|Articles|November 14, 2017
CRF Health’s TrialMax Touch® Selected for Pediatric Rare Disease Phase II Study
Advertisement
CRF Health has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study. CRF Health's TrialMax Touch® handheld device alone with other solutions will be utilized to collect quality of life readings and alleviate the burden of data entry for caregivers.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Upskilling Community Cancer Centers: A Training Pilot Hints at Promising Ways to Boost Oncology Clinical Research
2
When AI Learns to Speak Every Language: An eCOA Migration Study
3
Using Digital Tools to Enhance Patient-Centric Trials
4
Gilead’s ARTISTRY-2 Trial Shows Bictegravir Lenacapavir Combo Matches Biktarvy in Virologically Suppressed Adults With HIV
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
